Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3781-3794

  Chen, Hongwei ^a   Wang, Liya ^a   Yu, Qiqi ^a   Qian, Weiping ^a   Tiwari, Diana ^a   Yi, Hong ^b   Wang, Andrew Y ^c   Huang, Jing ^a   Yang, Lily ^a   Mao, Hui ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c OCEAN NANOTECH LLC   (United States)

Author keywords

Active targeting; Antifouling; Breast cancer; Magnetic nanoparticles; Magnetic resonance imaging

Indexed keywords

COPOLYMER; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNETIC IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; POLY(ETHYLENE OXIDE) BLOCK POLY(GAMMA METHACRYLOXYPROPYLTRIMETHOXYSILANE); SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CONJUGATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIVER; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PLASMA HALF LIFE; SPLEEN; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT;

ACTIVE TARGETING; ANTIFOULING; BREAST CANCER; MAGNETIC NANOPARTICLES; MAGNETIC RESONANCE IMAGING;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; COATED MATERIALS, BIOCOMPATIBLE; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-CHAIN ANTIBODIES;

EID: 84885029139     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S49069     Document Type: Article

References (51)

1. Weissleder R. Molecular imaging in cancer. Science. 2006;312(5777): 1168-1171.
2. Kim J, Piao Y, Hyeon T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem Soc Rev. 2009;38(2):372-390.
3. Joshi A, Bardhan R, Chen WX, et al. Tracking of multimodal thera-peutic nanocomplexes targeting breast cancer in vivo. Nano Lett. 2010; 10(12):4920-4928.
4. Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater. 2009;19(10):1553-1566.
5. Kuo WS, Chang CN, Chang YT, et al. Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew Chem Int Ed Engl. 2010;49(15):2711-2715.
6. Chow EK, Zhang XQ, Chen M, et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med. 2011;3(73).
7. Kim J, Lee JE, Lee SH, et al. Designed fabrication of a multifunc-tional polymer nanomedical platform for simultaneous cancer-targeted imaging and magnetically guided drug delivery. Adv Mater. 2008;20(3):478-483.
8. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47(28):5122-5135.
9. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-768.
10. Sarimollaoglu M, Nedosekin DA, Galanzha EI, Zharov VP. In vivo real-time monitoring of nanoparticle clearance rate from blood circula-tion using high speed flow cytometry. Proc SPIE. 2012;8427.
11. Nie SM. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine. 2010;5(4):523-528.
12. van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24(8):1405-1414.
13. Sheng Y, Liu CS, Yuan Y, et al. Long-circulating polymeric nano-particles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials. 2009;30(12):2340-2348.
14. 4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater. 2007;19(20):3163-3166.
15. Liu DF, Wu W, Ling JJ, Wen S, Gu N, Zhang XZ. Effective PEGyla-tion of iron oxide nanoparticles for high performance in vivo cancer imaging. Adv Funct Mater. 2011;21(8):1498-1504.
16. Reimhult E, Amstad E, Gillich T, Bilecka I, Textor M. Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. Nano Lett. 2009;9(12): 4042-4048.
17. Huang X, Peng X, Wang Y, Shin DM, El-Sayed MA, Nie S. A reex-amination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010;4(10):5887-5896.
18. Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006;128(22):7383-7389.
19. Lee H, Yu MK, Park S, et al. Thermally cross-linked superparamag-netic iron oxide nanoparticles: synthesis and application as a dual Imaging probe for cancer in vivo. J Am Chem Soc. 2007;129(42): 12739-12745.
20. Chen HW, Wu XY, Duan HW, et al. Biocompatible polysiloxane-containing diblock copolymer PEO-b-Pγ MPS for coating magnetic nanoparticles. ACS Appl Mater Interfaces. 2009;1(10):2134-2140.
21. Chen HW, Wang LY, Yeh J, et al. Reducing non-specific bind-ing and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgMPS copolymer coating. Biomaterials. 2010;31(20):5397-5407.
22. Yang LL, Mao H, Wang YA, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009;5(2):235-243.
23. Yu WW, Falkner JC, Yavuz CT, Colvin VL. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun (Camb). 2004(20):2306-2307.
24. Lee J, Choi Y, Kim K, et al. Characterization and cancer cell specific binding properties of anti-egfr antibody conjugated quantum dots. Bioconjug Chem. 2010;21(5):940-946.
25. Shukla R, Thomas TP, Desai AM, Kotlyar A, Park SJ, Baker JR. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology. 2008;19(29):295102.
26. Atkins RC. Colorimetric determination of iron in vitamin supple-ment tablets - general chemistry experiment. J Chem Educ. 1975; 52(8):550.
27. Bradford MM. Rapid and sensitive method for quantitation of micro-gram quantities of protein utilizing principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-254.
28. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316-327.
29. Yang L, Peng XH, Wang YA, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15(14): 4722-4732.
30. Bagwe RP, Hilliard LR, Tan WH. Surface modification of silica nano-particles to reduce aggregation and nonspecific binding. Langmuir. 2006;22(9):4357-4362.
31. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localiza-tion but does increase internalization in animal models. Cancer Res. 2006;66(13):6732-6740.
32. McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circula-tion time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology. 2007;18(38):385101.
33. Wang X, Li J, Wang YQ, et al. HFT-T, a targeting nanoparticle enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano. 2009;3(10):3165-3174.
34. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235-1240.
35. Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett. 2005;5(3):473-477.
36. Shukla R, Thomas TP, Peters JL, et al. HER2 specific tumor target-ing with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17(5):1109-1115.
37. Gao X, Yezhelyev MV, Al-Hajj A, et al. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv Mater. 2007;19(20):3146-3151.
38. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem. 2008;19(12):2321-2331.
39. Motamedi M, Eghtedari M, Liopo AV, Copland JA, Oraevslty AA. Engineering of hetero-functional gold nanorods for the in vivo molecu-lar targeting of breast cancer cells. Nano Lett. 2009;9(1):287-291.
40. Colombo M, Corsi F, Foschi D, et al. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches. Pharmacol Res. 2010; 62(2):150-165.
41. Suh JS, Lee JH, Huh YM, et al. Artificially engineered magnetic nano-particles for ultra-sensitive molecular imaging. Nat Med. 2007;13(1): 95-99.
42. Neoh KG, Wuang SC, Kang ET, Pack DW, Leckband DE. HER-2- mediated endocytosis of magnetic nanospheres and the implica-tions in cell targeting and particle magnetization. Biomaterials. 2008;29(14):2270-2279.
43. Yang HM, Park CW, Woo MA, et al. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR Imaging. Biomacromolecules. 2010;11(11):2866-2872.
44. 4 nanoparticles for target-specific platin delivery. J Am Chem Soc. 2009;131(12):4216-4217.
45. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311-321.
46. Zhang CF, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555-1562.
47. Lee MJE, Veiseh O, Bhattarai N, et al. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One. 2010;5(3):e9536.
48. Mitruka BM, Rawnsley HM. Clinical, Biochemical and Hemato-logical Reference Values in Normal Experimental Animals and Normal Humans. New York, NY: Masson Publishing; 1981.
49. Chou SW, Shau YH, Wu PC, Yang YS, Shieh DB, Chen CC. In vitro and in vivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging. J Am Chem Soc. 2010;132(38):13270-13278.
50. Sinha R, Kim GJ, Nie S., Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5(8):1909-1917.
51. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241-263.